Rapamycin

Target: This ligand targets FKBP12 and the FRB domain of mTOR in biochemical or cellular target-engagement studies.

Mechanism of Action: Rapamycin can serve as a high-affinity FKBP12-binding module that simultaneously engages the mTOR FRB domain, providing a chemically induced proximity paradigm relevant to degrader design. In PROTAC-like systems, a rapamycin-derived recognition element can be linked to an E3 ligase ligand or paired with engineered recruitment strategies to juxtapose the protein of interest with ubiquitination machinery. Productive assembly depends on maintaining FKBP12 or FRB engagement while optimizing linker length and orientation. Favorable ternary geometry can then enable target ubiquitination and proteasomal clearance in experimental models.

• PROTAC E3 Ligase Recruiting: Rapamycin-based ligands can be used as high-affinity recruiters of the FKBP12 E3 ligase in PROTAC designs. By conjugating Rapamycin derivatives to a target-binding moiety, researchers can induce proximity-driven ubiquitination and subsequent proteasomal degradation of the protein of interest, enabling systematic evaluation of degradation efficiency and selectivity.

• Multivalent Target Degradation: Rapamycin scaffolds support modular PROTAC architectures that can be tuned for linker length, geometry, and binding valency. This enables optimization of ternary complex formation between the target protein, FKBP12, and the PROTAC, often improving degradation potency while allowing comparative studies across related targets and structural analogs.

• Ternary Complex Mechanism Studies: Rapamycin-dependent FKBP12 recruitment is well suited for mechanistic studies of PROTAC action. Researchers can investigate how ternary complex stability correlates with ubiquitination kinetics and degradation outcomes, using biochemical assays and cell-based readouts to map the determinants of productive engagement versus non-degradative binding.

• Proteasome-Dependent Pathway Validation: Rapamycin-based PROTAC systems are commonly employed to confirm that observed target loss proceeds through ubiquitin–proteasome degradation. Experimental workflows can include proteasome inhibition and ubiquitination assays to verify pathway dependence, distinguish degradation from transcriptional or translational effects, and quantify degradation rates under controlled conditions.

Rapamycin is a FKBP-family ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.

Structure: The structure of Rapamycin is characterized by phenol or alcohol functionality; macrocyclic or peptidomimetic scaffold. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The hydroxy or phenolic motif can be considered for ether, carbonate, carbamate, or ester linker attachment after SAR verification. For FKBP-directed chemical biology, it may be connected to degradation or dimerization modules through flexible PEG/alkyl or amide-containing linkers, subject to FKBP-binding SAR. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.